Heart failure (HF) affects 3.6% of the Canadian population costing >$3 billion annually. Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous, chronic and progressive clinical syndrome characterized by impaired heart function and accounts for 50% of all HF cases, with its incidence growing at a rate of 10% per decade. The prevalence of HFpEF in females is twice as high as in males. Ironically, there are significant barriers to treating HFpEF patients, making diagnosis and patient follow-up extremely difficult while further hindering the development of novel therapeutics and escalating the cost of drug discovery. This unmet medical need can be tackled by mapping the molecular landscape of defective hearts from HFpEF patients and preclinical HFpEF models to develop an atlas of HFpEF pathogenesis that would directly benefit the clinical and industry stakeholders. Dalhousie Medicine New Brunswick (DMNB) cardiovascular researchers (DalCREW) embarked on a collaborative interdisciplinary research program for heart failure prevention and treatment (RESOLVE) and successfully secured a CFI-IF grant in June 2023. To execute the RESOLVE program, success at CFI-IF funding was timely to acquire cutting-edge infrastructure for discovering novel solutions for HFpEF treatment. Over the long term, CFI-IF and NBIF partner-matched funding will allow us to: 1) elucidate novel drug targets for HFpEF treatment; 2) decrease healthcare costs; 3) expand technological repertoire, collaboration, and commercialization with industries, 4) enhance HQP training to create a skilled workforce in cardiovascular sciences in the Maritimes; and 5) improve the health and quality of life for Canadians.